# Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects Who Are Intolerant to Statins

Study · id `cardio:ct-nct02135029` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02135029](<https://clinicaltrials.gov/study/NCT02135029>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT02135029

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 184 participants.

## Technical summary

Registry record NCT02135029. Randomized; quadruple masking; primary purpose treatment. Start 2014-06 (actual); primary completion 2015-11 (actual). Results posted on 2017-12-14.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 184 participants (enrolled count; ClinicalTrials.gov record NCT02135029, source copy `cardio:ctgov-nct02135029-2017-12-14`, retrieved 2026-10-31)
- Started: 2014-06 (actual) (ClinicalTrials.gov record NCT02135029, source copy `cardio:ctgov-nct02135029-2017-12-14`, retrieved 2026-10-31)
- Primary completion: 2015-11 (actual) (ClinicalTrials.gov record NCT02135029, source copy `cardio:ctgov-nct02135029-2017-12-14`, retrieved 2026-10-31)
- Completion: 2015-11 (actual) (ClinicalTrials.gov record NCT02135029, source copy `cardio:ctgov-nct02135029-2017-12-14`, retrieved 2026-10-31)
- Results first posted: 2017-12-14 (ClinicalTrials.gov record NCT02135029, source copy `cardio:ctgov-nct02135029-2017-12-14`, retrieved 2026-10-31)
- Countries: United States; Canada (ClinicalTrials.gov record NCT02135029, source copy `cardio:ctgov-nct02135029-2017-12-14`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02135029-2017-12-14`, retrieved 2026-10-31)

## The registry's words

- Brief title: Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects Who Are Intolerant to Statins
- Acronym: SPIRE-SI
- Condition: Hyperlipidemia
- Intervention (Drug): Bococizumab (PF-04950615;RN316)
- Intervention (Drug): Atorvastatin
- Intervention (Other): Placebo for Bococizumab (PF-04950615;RN316)
- Intervention (Other): Placebo for atorvastatin
- Lead sponsor: Pfizer
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry intervention name matches this record: Atorvastatin (`cardio:atorvastatin`)
- Registry lists this organization as the lead sponsor: Pfizer (`cardio:org-pfizer`)

## Provenance

Content hash: ea207b443b81a6dc9b669f16bc38edbffeef751ccd673597f3c28642eb62595c
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
